Company news

Amgen Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Amgen announces webcast of 2022 morgan stanley global healthcare conference

September 7, 2022

Amgen announces positive new data at eadv 2022 for Otezla® (apremilast)

September 7, 2022

Amgen to webcast investor call at esmo 2022

September 6, 2022

Amgen announces webcast of 2022 wells fargo healthcare conference

September 1, 2022

Amgen announces webcast of 2022 citi global healthcare conference

September 1, 2022

Amgen to present new, positive clinical and real-world data across inflammation portfolio at EADV 2022

August 29, 2022

Amgen announces topline data from LUMAKRAS® (sotorasib) Phase 3 trial in non-small cell lung cancer

August 29, 2022

Amgen announces positive top-line results from Phase 3 study of ABP 959, biosimilar candidate to SOLIRIS® (eculizumab)

August 22, 2022

Amgen reports second quarter 2022 financial results

August 3, 2022

Amgen appoints Michael V. Drake to board of directors

August 2, 2022

Amgen announces webcast of 2022 second quarter financial results

July 31, 2022

Amgen announces webcast of 2022 jefferies healthcare conference

June 2, 2022

Amgen announces positive topline Phase 2 data for investigational olpasiran in adults with elevated Lipoprotein(a)

May 30, 2022

Amgen and Lance Bass partner to encourage people to do a 'Double Take' to recognize the early signs of psoriatic arthritis

May 11, 2022

Amgen releases annual environmental, social & governance report

May 1, 2022

Amgen announces results from two open label extension studies of Repatha® (evolocumab)

April 26, 2022

Amgen announces positive top-line results from Phase 3 study of ABP 654, biosimilar candidate to STELARA® (ustekinumab)

April 17, 2022

Amgen announces new Otezla (apremilast) data at AAD congress 2022

March 24, 2022

Amgen to present long-term outcomes for LUMAKRAS® (sotorasib) in KRAS G12C-mutated NSCLC at AACR 2022

March 7, 2022

Global biotechnology leader Amgen breaks ground on new manufacturing facility in North Carolina

March 6, 2022

Amgen announces 2022 second quarter dividend

March 1, 2022

Amgen issues inaugural green bond to advance ESG goals

February 21, 2022

Amgen outlines growth strategy through 2030 at virtual business review

February 7, 2022

Amgen reports fourth quarter and full year 2021 financial results

February 6, 2022

Amgen and Plexium announce multi-year, drug discovery collaboration to identify novel targeted protein degradation therapies

February 2, 2022

Amgen and Arrakis Therapeutics announce multi-target collaboration to identify novel RNA degrader small molecule Therapeutics

January 10, 2022

Amgen and BioLabs LA at The Lundquist Institute announce that Karma Biotechnologies will receive the second Amgen Golden Ticket

January 9, 2022

Amgen and Generate Biomedicines announce multi-target, multi-modality research collaboration agreement

January 5, 2022

Amgen Announces New Data Being Presented At ASH 2021

December 5, 2021

Amgen Announces 10% Increase In 2022 First Quarter Dividend

December 2, 2021

Amgen Announces Positive Top-Line Results From Otezla® (apremilast) Phase 3 DISCREET Study In Moderate To Severe Genital Psoriasis

November 30, 2021

Amgen Awards The Bath Institute of Rheumatic Diseases $25,000 Through UPLIFT Innovation Challenge

November 16, 2021

Amgen Begins Construction On New Biomanufacturing Plant In Central Ohio

November 4, 2021

Amgen Reports Third Quarter 2021 Financial Results

November 1, 2021

Amgen Announces 2021 Fourth Quarter Dividend

October 20, 2021

Amgen Successfully Completes Acquisition Of Teneobio, Inc.

October 18, 2021

Amgen Announces New LUMAKRAS™ (sotorasib) Combination Data From Phase 1b CodeBreaK 101 Study In Patients With KRAS G12C-mutated Cancers At AACR-NCI-EORTC 2021

October 6, 2021

Amgen Announces New Data Highlighting Global Trends In Hip Fracture Incidence And Treatment

October 3, 2021

Amgen Releases 8th Edition of Biosimilar Trends Report

September 21, 2021

Amgen Wins Patent Case on Otezla® (apremilast)

September 19, 2021

Amgen To Showcase New Data From Inflammation Portfolio At EADV Virtual Congress 2021

September 12, 2021

Amgen Presents New Data From Thoracic Oncology Portfolio At WCLC21

September 7, 2021

Amgen Reports Second Quarter 2021 Financial Results

August 2, 2021

Amgen Announces 2021 Third Quarter Dividend

July 29, 2021

Amgen Appoints S. Omar Ishrak To Board Of Directors

July 28, 2021

Amgen To Acquire Privately Held Teneobio For $900 Million In Cash With Future Contingent Milestone Payments

July 26, 2021

Amgen And The International Federation of Psoriasis Associations Launch UPLIFT Innovation Challenge

July 13, 2021

Amgen Announces Approval Of Aimovig® (Erenumab) In Japan For The Suppression Of Onset Of Migraine Attacks In Adults

June 22, 2021

Amgen to Webcast Investor Meeting at ASCO 2021

May 31, 2021

Amgen Announces Tezepelumab Biologics License Application Submitted To U.S. FDA

May 9, 2021

← Newer news releases · Older news releases →

Calls

The 5 newest of 29 calls. Every call is listed under its year.

Decks

The 5 newest of 28 decks. Every deck is listed under its year.